Nobelpharma America is the first global subsidiary of Nobelpharma Co. Ltd (“Nobelpharma”), headquartered in Tokyo, Japan. Founded in 2003, Nobelpharma received its first drug approval in Japan in 2008. Since then, Nobelpharma has received approvals for over 15 drugs and devices in Japan across a wide range of indications, bringing life-changing treatments to patients, caregivers, and health care providers.

Our company’s mission includes addressing unmet needs and closing gaps in patient care: we develop drugs and medical devices for diseases that often go overlooked because of the rarity and small number of impacted individuals. Examples include patients suffering from tuberous sclerosis complex (TSC) and adductor spasmodic dysphonia.

To kick start launch activities, Nobelpharma America chose Bethesda, MD as the U.S. Headquarters because of the proximity to leading U.S. researchers, regulators, and advocacy groups including the TSC Alliance. We look forward to working closely with the TSC Alliance, and other organizations, to help improve the lives of people living with diseases that have no approved treatments, yet.